SIGA Technologies, Inc. (NASDAQ:SIGA – Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 1,200 call options on the stock. This is an increase of 1,438% compared to the average volume of 78 call options.
Institutional Investors Weigh In On SIGA Technologies
Several hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. grew its position in SIGA Technologies by 251.2% in the 2nd quarter. American Century Companies Inc. now owns 841,759 shares of the company’s stock valued at $6,389,000 after acquiring an additional 602,091 shares during the last quarter. First Wilshire Securities Management Inc. lifted its holdings in SIGA Technologies by 14.4% during the 4th quarter. First Wilshire Securities Management Inc. now owns 2,362,107 shares of the company’s stock valued at $13,228,000 after buying an additional 297,095 shares in the last quarter. Denali Advisors LLC purchased a new stake in SIGA Technologies in the 2nd quarter valued at about $1,815,000. Campbell & CO Investment Adviser LLC grew its stake in SIGA Technologies by 453.4% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 218,953 shares of the company’s stock worth $1,226,000 after acquiring an additional 179,388 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new position in SIGA Technologies in the first quarter worth approximately $1,367,000. 55.40% of the stock is currently owned by hedge funds and other institutional investors.
SIGA Technologies Stock Performance
NASDAQ:SIGA opened at $7.97 on Friday. The firm has a market capitalization of $568.82 million, a PE ratio of 7.25 and a beta of 0.91. The stock’s fifty day moving average is $9.04 and its 200 day moving average is $8.08. SIGA Technologies has a fifty-two week low of $4.22 and a fifty-two week high of $12.83.
About SIGA Technologies
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Recommended Stories
- Five stocks we like better than SIGA Technologies
- Top Stocks Investing in 5G Technology
- Emerging Markets: What They Are and Why They Matter
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Recession or Not, These 3 Stocks Are Winners
- What is the Dow Jones Industrial Average (DJIA)?
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.